VALBONNE, France--(BUSINESS WIRE)--Regulatory News:
TxCell SA (FR0010127662 – TXCL) (Paris:TXCL), a developer of cellular immunotherapies based on regulatory T cells (Tregs) for inflammation, autoimmunity and transplantation, today announces it will participate and present at the first Treg Directed Therapies Summit to be held in Boston on May 22-24, 2018.
This summit, a first of its kind, will gather academic and industry experts in the field of Treg-based in vivo and ex vivo therapies development. The theme of the conference will be the discovery and production of stable, persistent and targeted Treg directed therapies that accelerate clinical development.
Pierre Heimendinger, PhD, VP Pharmaceutical Development of TxCell, will lead a workshop entitled “New Approaches to Improving Cell Yield, Process Efficiency and Therapeutic Potency in Clinical Regulatory T Cell Manufacturing Processes” (May 22, 1 pm EST). He will also chair a round table discussion entitled “Identify Key Manufacturing Considerations to Ensure Feasible Large Scale Clinical Trials” (May 24, 2.30 pm EST).
In the section titled “Comparison of Trafficking Approaches to Achieve Antigen Specific Tolerance”, Stéphane Boissel, CEO of TxCell, will present TxCell’ specific approach to engineer Tregs for autoimmunity, inflammation and transplantation (May 24, 3.40 pm EST).
“The cross-industry demand for this summit as well as the quality of the panels and of the audience is a demonstration of the growing interest for the therapeutic potential of regulatory T cells,” said Stéphane Boissel, CEO, TxCell. “With over a decade of experience in the biology of this cell population, and a unique engineered CAR Treg cell platform, we believe that TxCell is well positioned to benefit from this new momentum.”
About TxCell – www.txcell.com
TxCell is a biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe inflammatory and autoimmune diseases with high unmet medical need. TxCell is targeting transplantation as well as a range of autoimmune diseases (both T-cell and B-cell-mediated), such as multiple sclerosis, rheumatoid arthritis, inflammatory bowel diseases or inflammatory skin diseases.
TxCell’s cellular immunotherapies are based on regulatory T lymphocytes (Tregs). Tregs are a T cell population discovered in the nineties for which anti-inflammatory properties have been demonstrated. Contrary to conventional approaches based on non-specific polyclonal Tregs, TxCell is exclusively developing engineered antigen-specific Tregs, where the antigen specificity is brought by a Chimeric Antigen Receptor (CAR) (CAR-Treg cells).
Based in Sophia-Antipolis, France, TxCell is listed on Euronext Paris and currently has 46 employees.
This press release contains certain forward-looking statements relating to the business of TxCell, which shall not be considered per se as historical facts, including TxCell’s ability to develop, market, commercialize and achieve market acceptance for specific products, estimates for future performance and estimates regarding anticipated operating losses, future revenues, capital requirements, needs for additional financing. In addition, even if the actual results or development of TxCell are consistent with the forward-looking statements contained in this press release, those results or developments of TxCell may not be indicative of their in the future.
In some cases, you can identify forward-looking statements by words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," "aims," "targets," or similar words. Although the management of TxCell believes that these forward-looking statements are reasonably made, they are based largely on the current expectations of TxCell as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of TxCell could be affected by, among other things, uncertainties involved in the development of the Company’s products, which may not succeed, or in the delivery of TxCell’s products marketing authorizations by the relevant regulatory authorities and, in general, any factor that could affects TxCell capacity to commercialize the products it develops, as well as, any other risk and uncertainties developed or identified in any public documents filed by TxCell with the AMF, included those listed in chapter 4 “Risk factors” of the 2017 document de référence (registration document) submitted to the AMF on April 25, 2018. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Notwithstanding the compliance with article 223-1 of the General Regulation of the AMF (the information disclosed must be “accurate, precise and fairly presented”), TxCell is providing the information in these materials as of this press release, and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.